Strategic advisory for life sciences and healthcare, where scientific depth meets commercial judgement
We bring a business mindset coupled with deep scientific rigor. Every recommendation is actionable and empirically grounded.
Every strategic recommendation is made with execution in mind. We pressure-test it in the market, make introductions that move it forward, and refine the approach as conditions change.
Our thinking draws on long-standing relationships with operators, executives, scientists and investors across life sciences and healthcare, which bring candid perspectives that rarely make it into published reports.
We advise on what serves your long-term position. If the evidence says walk away from a deal or a market, that is our recommendation, whatever it means for our fee.
“We’d rather lose a fee than a client.”
Clients served across corporates, start-ups and investors
transactions closed in a short period of our journey
years combined life sciences and healthcare strategy experience across the team
Companies and investors in our network across the UK, US, India and Africa.
We help you identify the right move and see it through to close. Engage us for a single stage or the full journey.
Strategy and intelligence
Capital and transactions
Strategy and intelligence
Not just compiling data, but defining where you have the right to win, and why. Positioning, roadmap and go-to-market rooted in customer economics.
Strategy and intelligence
Not paid interviews, but operator- and investor-level insight into the true state of the industry, mapped directly to the decision in front of you.
Strategy and intelligence
Technical and commercial diligence on assets, platforms and companies, so the science is tested before the capital is committed.
Capital and transactions
Buy-side and sell-side support that gets you across the line: from the expansion thesis and the target universe to valuation, structuring and diligence.
Capital and transactions
Build, buy or partner: we develop and test the partnership thesis that accelerates your roadmap, then help structure deals that work for both sides.
Capital and transactions
How much to raise, when, and from whom, to protect dilution and reach the next milestone. Then the story, the model and the investor process.
Startup advisory
We operate as an extension of the founding team, aligning science, business and execution. Bring us in across all five pillars, or on the one that matters most right now.
Insights
Case studies and market outlooks, along with The BioStrat Brief, our newsletter offering a dealmaker’s view on fundraising, M&A, strategy and markets.





FAQ
We are a strategic advisory firm that works in life sciences and healthcare. We run two practices. For established companies we work on market intelligence, growth strategy, new markets and partnering, which usually leads into transactions: M&A, fundraising and licensing. For a small number of start-ups we act as long-term advisors on go-to-market, partnering and fundraising. Most of our engagements end with transactions: fundraise, a licensing deal or an M&A process.
None of the three exactly. We are strategic advisors who also run transactions. We do not chase whichever space is fashionable or force a deal: we start from where the science and the business can genuinely win, then run the process to get there. We do not manage a fund of our own. We bring in investors, partners and acquirers from our network and manage the process with you.
Biopharma, Pharma services, diagnostics and genomics, digital health, TechBio, CROs and healthcare services. We do bring an unparalleled depth in tech X life sciences space. We work with founders from pre-seed onwards, with scaled and profitable companies on a range of projects including sell side advisory, and with corporates and private equity on the buy side.
Usually a modest retainer plus a success fee. The retainer covers the preparation work that decides the outcome; the success fee is paid only when a transaction closes, and as a percentage it falls as the deal size rises. Most of what we earn, we earn when you do. Start-up engagements can be structured differently.
Yes, on an anonymized basis. Examples include a seed round for a pharma commercial analytics AI platform, sale processes for data and bioinformatics services businesses, a buy-side platform search for a global CRO, and a technology-enabled M&A landscape for a commercialisation services group. We name clients only with their permission. Reach out to see if we have more examples from your exact space.
A business to grow, a capital raise or M&A discussion on cards, let's talk
Strategic advisory for life sciences and healthcare, where scientific depth meets commercial judgement
We bring a business mindset coupled with deep scientific rigor. Every recommendation is actionable and empirically grounded.
Every strategic recommendation is made with execution in mind. We pressure-test it in the market, make introductions that move it forward, and refine the approach as conditions change.
Our thinking draws on long-standing relationships with operators, executives, scientists and investors across life sciences and healthcare, which bring candid perspectives that rarely make it into published reports.
This piece is a core pillar of our work.
We advise on what serves your long-term position. If the evidence says walk away from a deal or a market, that is our recommendation, whatever it means for our fee.
“We’d rather lose a fee than a client.”
Clients served across corporates, start-ups and investors
transactions closed in a short period of our journey
years combined life sciences and healthcare strategy experience across the team
Companies and investors in our network across the UK, US, India and Africa.
We help you identify the right move and see it through to close. Engage us for a single stage or the full journey.
Strategy and intelligence
Not just compiling data, but defining where you have the right to win, and why. Positioning, roadmap and go-to-market rooted in customer economics.
Not paid interviews, but operator- and investor-level insight into the true state of the industry, mapped directly to the decision in front of you.
Technical and commercial diligence on assets, platforms and companies, so the science is tested before the capital is committed.
Capital and transactions
Buy-side and sell-side support that gets you across the line: from the expansion thesis and the target universe to valuation, structuring and diligence.
Build, buy or partner: we develop and test the partnership thesis that accelerates your roadmap, then help structure deals that work for both sides.
How much to raise, when, and from whom, to protect dilution and reach the next milestone. Then the story, the model and the investor process.
Startup advisory
We operate as an extension of the founding team, aligning science, business and execution.
Insights
Case studies and market outlooks, along with The BioStrat Brief, our newsletter offering a dealmaker’s view on fundraising, M&A, strategy and markets.





FAQ
We are a strategic advisory firm that works in life sciences and healthcare. We run two practices. For established companies we work on market intelligence, growth strategy, new markets and partnering, which usually leads into transactions: M&A, fundraising and licensing. For a small number of start-ups we act as long-term advisors on go-to-market, partnering and fundraising. Most of our engagements end with transactions: fundraise, a licensing deal or an M&A process.
None of the three exactly. We are strategic advisors who also run transactions. We do not chase whichever space is fashionable or force a deal: we start from where the science and the business can genuinely win, then run the process to get there. We do not manage a fund of our own. We bring in investors, partners and acquirers from our network and manage the process with you.
Biopharma, Pharma services, diagnostics and genomics, digital health, TechBio, CROs and healthcare services. We do bring an unparalleled depth in tech X life sciences space. We work with founders from pre-seed onwards, with scaled and profitable companies on a range of projects including sell side advisory, and with corporates and private equity on the buy side.
Usually a modest retainer plus a success fee. The retainer covers the preparation work that decides the outcome; the success fee is paid only when a transaction closes, and as a percentage it falls as the deal size rises. Most of what we earn, we earn when you do. Start-up engagements can be structured differently.
Yes, on an anonymized basis. Examples include a seed round for a pharma commercial analytics AI platform, sale processes for data and bioinformatics services businesses, a buy-side platform search for a global CRO, and a technology-enabled M&A landscape for a commercialisation services group. We name clients only with their permission. Reach out to see if we have more examples from your exact space.
A business to grow, a capital raise or M&A discussion on cards, let's talk
Strategic advisory for life sciences and healthcare, where scientific depth meets commercial judgement
We bring a business mindset coupled with deep scientific rigor. Every recommendation is actionable and empirically grounded.
Every strategic recommendation is made with execution in mind. We pressure-test it in the market, make introductions that move it forward, and refine the approach as conditions change.
Our thinking draws on long-standing relationships with operators, executives, scientists and investors across life sciences and healthcare, which bring candid perspectives that rarely make it into published reports.
This piece is a core pillar of our work.
We advise on what serves your long-term position. If the evidence says walk away from a deal or a market, that is our recommendation, whatever it means for our fee.
“We’d rather lose a fee than a client.”
Clients served across corporates, start-ups and investors
transactions closed in a short period of our journey
years combined life sciences and healthcare strategy experience across the team
Companies and investors in our network across the UK, US, India and Africa.
We help you identify the right move and see it through to close. Engage us for a single stage or the full journey.
Strategy and intelligence
Not just compiling data, but defining where you have the right to win, and why. Positioning, roadmap and go-to-market rooted in customer economics.
Not paid interviews, but operator- and investor-level insight into the true state of the industry, mapped directly to the decision in front of you.
Technical and commercial diligence on assets, platforms and companies, so the science is tested before the capital is committed.
Capital and transactions
Buy-side and sell-side support that gets you across the line: from the expansion thesis and the target universe to valuation, structuring and diligence.
Build, buy or partner: we develop and test the partnership thesis that accelerates your roadmap, then help structure deals that work for both sides.
How much to raise, when, and from whom, to protect dilution and reach the next milestone. Then the story, the model and the investor process.
Startup advisory
We operate as an extension of the founding team, aligning science, business and execution.
Insights
Case studies and market outlooks, along with The BioStrat Brief, our newsletter offering a dealmaker’s view on fundraising, M&A, strategy and markets.





FAQ
We are a strategic advisory firm that works in life sciences and healthcare. We run two practices. For established companies we work on market intelligence, growth strategy, new markets and partnering, which usually leads into transactions: M&A, fundraising and licensing. For a small number of start-ups we act as long-term advisors on go-to-market, partnering and fundraising. Most of our engagements end with transactions: fundraise, a licensing deal or an M&A process.
None of the three exactly. We are strategic advisors who also run transactions. We do not chase whichever space is fashionable or force a deal: we start from where the science and the business can genuinely win, then run the process to get there. We do not manage a fund of our own. We bring in investors, partners and acquirers from our network and manage the process with you.
Biopharma, Pharma services, diagnostics and genomics, digital health, TechBio, CROs and healthcare services. We do bring an unparalleled depth in tech X life sciences space. We work with founders from pre-seed onwards, with scaled and profitable companies on a range of projects including sell side advisory, and with corporates and private equity on the buy side.
Usually a modest retainer plus a success fee. The retainer covers the preparation work that decides the outcome; the success fee is paid only when a transaction closes, and as a percentage it falls as the deal size rises. Most of what we earn, we earn when you do. Start-up engagements can be structured differently.
Yes, on an anonymized basis. Examples include a seed round for a pharma commercial analytics AI platform, sale processes for data and bioinformatics services businesses, a buy-side platform search for a global CRO, and a technology-enabled M&A landscape for a commercialisation services group. We name clients only with their permission. Reach out to see if we have more examples from your exact space.
A business to grow, a capital raise or M&A discussion on cards, let's talk